Immunologic Monitoring and Cellular Products Laboratory (IMCPL) The goals of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) are to support the development of cellular, viral or gene therapies for cancer and monitor immunological responses to these therapies in patents enrolled in clinical trials at the Hillman Cancer Center (HCC). IMCPL is a unique facility offering a comprehensive set of state-of-the-art technologies and assays to the HCC investigators conducting clinical trials with various biotherapies and monitoring immune responses to these therapies. IMCPL also supports pre-clinical developmental projects for future translation to clinical trials. IMCPL is led by Dr. Theresa Whiteside, (CII) who oversees a staff of 20 FTE in the facility located within the HCC Research Pavilion. Services are provided by trained personnel in a CLIA/CAP certified laboratory with independent quality assurance (QA) oversight. IMCPL primarily supports the clinical and translational CII and CT research programs. In FY2019, the IMCPL serviced 62 independent clinical trials for 35 HCC members (87% of the usage)/research protocols, all relevant to the HCC mission of providing novel immunotherapy-driven clinical trials to cancer patients. During the next project period, IMCPL will add 9 new clean rooms, thus expanding therapeutic cell production capabilities and plans to increase the repertoire of cellular products for therapy in the future. It is also upgrading its monitoring capabilities to analyses of single-cell and exosome molecular profiles.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Redner, Robert L; Beumer, Jan H; Kropf, Patricia et al. (2018) A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma 59:2595-2601
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478
Menk, Ashley V; Scharping, Nicole E; Moreci, Rebecca S et al. (2018) Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions. Cell Rep 22:1509-1521
Shiffman, Saul; Scholl, Sarah M (2018) Three approaches to quantifying cigarette consumption: Data from nondaily smokers. Psychol Addict Behav 32:249-254
Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72
Frahm, Krystle A; Waldman, Jacob K; Luthra, Soumya et al. (2018) A comparison of the sexually dimorphic dexamethasone transcriptome in mouse cerebral cortical and hypothalamic embryonic neural stem cells. Mol Cell Endocrinol 471:42-50
Pulopulos, Matias M; Vanderhasselt, Marie-Anne; De Raedt, Rudi (2018) Association between changes in heart rate variability during the anticipation of a stressful situation and the stress-induced cortisol response. Psychoneuroendocrinology 94:63-71
Moravcikova, Erika; Meyer, E Michael; Corselli, Mirko et al. (2018) Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC). Cytometry A 93:894-904
Samuelsson, Laura B; Bovbjerg, Dana H; Roecklein, Kathryn A et al. (2018) Sleep and circadian disruption and incident breast cancer risk: An evidence-based and theoretical review. Neurosci Biobehav Rev 84:35-48

Showing the most recent 10 out of 1187 publications